ELX-02   Click here for help

GtoPdb Ligand ID: 10944

Synonyms: CS-0095334 | ELX-02 (disulfate) | HY-114231B
Compound class: Synthetic organic
Comment: ELX-02 is a compound designed to restore CFTR function in people with CF who have nonsense mutations. Nonsense mutations (also known as “x” or “stop” mutations) in the CFTR gene cause the production of CFTR protein to stop prematurely. ELX-02 is intended allow lung cells to override these premature stop signals and make full-length, functional CFTR protein.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 14
Hydrogen bond donors 10
Rotatable bonds 6
Topological polar surface area 262.38
Molecular weight 482.26
XLogP -3.89
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N[C@H]1C[C@@H](N)[C@@H]([C@H]([C@@H]1O[C@H]1O[C@H]([C@H](O)C)[C@H]([C@@H]([C@H]1N)O)O)O[C@@H]1O[C@@H]([C@H]([C@H]1O)O)[C@@H](N)C)O
Isomeric SMILES N[C@H]1C[C@@H](N)[C@@H]([C@H]([C@@H]1O[C@H]1O[C@H]([C@H](O)C)[C@H]([C@@H]([C@H]1N)O)O)O[C@@H]1O[C@@H]([C@H]([C@H]1O)O)[C@@H](N)C)O
InChI InChI=1S/C19H38N4O10/c1-4(20)14-12(28)13(29)19(30-14)33-17-9(25)6(21)3-7(22)16(17)32-18-8(23)10(26)11(27)15(31-18)5(2)24/h4-19,24-29H,3,20-23H2,1-2H3/t4-,5+,6+,7-,8+,9-,10+,11-,12-,13+,14+,15+,16+,17+,18+,19-/m0/s1
InChI Key KJBRSTPUILEBDR-DBMIJKFDSA-N
No information available.
Summary of Clinical Use Click here for help
A synthetic eukaryotic ribosome-selective aminoglycoside optimized as a translational read‐through molecule that induces read through of nonsense mutations, resulting in normally localized full‐length functional proteins. Is being developed (as ELX-02 (disulfate)) as a therapy for genetic diseases caused by nonsense mutations, in particular for CTNSW138X translational read-through in patients with cystinosis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04069260 A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis Phase 2 Interventional Eloxx Pharmaceuticals, Inc.